May 18, 2021 -- Clover Biopharmaceuticals said that its second-generation, protein-based COVID-19 vaccine candidate has demonstrated in preclinical testing that it can provide broad neutralization of the original SARS-CoV-2 strain as well as variants of concern.
Mice that were vaccinated with two doses of the modified B.1.351 Spike (S)-Trimer at day 0 and day 21 showed strong humoral immune responses that broadly neutralize the original SARS-CoV-2 variants first identified in South Africa (B.1.351), Brazil (P.1), and the U.K. (B.1.1.7), according to Clover.
In other results, the researchers reported that immunization with two doses of Clover's SCB-2019 first-generation vaccine candidate and a third booster dose on day 35 of either SCB-2019 or B.1.351 S-Trimer increased cross-reactive neutralizing antibodies against B.1.351. These findings demonstrate the potential importance of booster doses, according to Clover.
The research is available as a preprint on bioRxiv and also will be submitted for a peer-review publication, the company said. Clover said it intends to continue evaluation of B.1.351 S-Trimer and advance a second-generation COVID-19 vaccine candidate into clinical trials in the second half of 2021.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
